UY31669A1 - "PHARMACEUTICAL FORMULATION THAT INCLUDES OXABISPIDINS / 236" - Google Patents

"PHARMACEUTICAL FORMULATION THAT INCLUDES OXABISPIDINS / 236"

Info

Publication number
UY31669A1
UY31669A1 UY031669A UY31669A UY31669A1 UY 31669 A1 UY31669 A1 UY 31669A1 UY 031669 A UY031669 A UY 031669A UY 31669 A UY31669 A UY 31669A UY 31669 A1 UY31669 A1 UY 31669A1
Authority
UY
Uruguay
Prior art keywords
oxabispidins
pharmaceutical formulation
pharmaceutically acceptable
oxabispidines
prevention
Prior art date
Application number
UY031669A
Other languages
Spanish (es)
Inventor
Kristina Roos
Hans Joensson
Hans Carlsson
Anders R Berggren
Erik Snderlind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UY31669A1 publication Critical patent/UY31669A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una formulación farmacéutica de liberación modificada que comprende oxabispidinas como ingrediente activo, o una sal farmacéuticamente aceptable del mismo; y un diluyente o vehículo farmacéuticamente aceptable, para ser utilizado en el tratamiento o prevención de las arritmias cardíacas.A pharmaceutical modified release formulation comprising oxabispidines as an active ingredient, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable diluent or carrier, to be used in the treatment or prevention of cardiac arrhythmias.

UY031669A 2008-02-22 2009-02-20 "PHARMACEUTICAL FORMULATION THAT INCLUDES OXABISPIDINS / 236" UY31669A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3064308P 2008-02-22 2008-02-22

Publications (1)

Publication Number Publication Date
UY31669A1 true UY31669A1 (en) 2009-09-30

Family

ID=40985767

Family Applications (1)

Application Number Title Priority Date Filing Date
UY031669A UY31669A1 (en) 2008-02-22 2009-02-20 "PHARMACEUTICAL FORMULATION THAT INCLUDES OXABISPIDINS / 236"

Country Status (5)

Country Link
AR (1) AR070617A1 (en)
PE (1) PE20091464A1 (en)
TW (1) TW200940110A (en)
UY (1) UY31669A1 (en)
WO (1) WO2009105023A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104586809A (en) * 2015-01-08 2015-05-06 浙江亚太药业股份有限公司 Esomeprazole magnesium enteric pill coated tablet and preparation method thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US6344215B1 (en) * 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
TWI259836B (en) * 2001-04-12 2006-08-11 Astrazeneca Ab Modified release formulation suitable for antiarrhythmic compounds
US8367111B2 (en) * 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
CN101243093A (en) * 2005-06-13 2008-08-13 阿斯利康(瑞典)有限公司 New oxabispidine compounds for the treatment of cardiac arrhythmias
WO2007083323A2 (en) * 2006-01-23 2007-07-26 Panacea Biotec Limited. Modified release oral dosage form comprising desmopressin
EP2018157A2 (en) * 2006-04-26 2009-01-28 Astron Research Limited Controlled release formulation comprising anti-epileptic drugs

Also Published As

Publication number Publication date
PE20091464A1 (en) 2009-10-24
TW200940110A (en) 2009-10-01
AR070617A1 (en) 2010-04-21
WO2009105023A1 (en) 2009-08-27

Similar Documents

Publication Publication Date Title
AR084691A1 (en) TOPICAL USE FORMULATION FOR A JAK INHIBITOR AND METHOD TO TREAT SKIN DISORDER
ECSP088560A (en) FORMULATION OF SUSTAINED RELEASE THAT INCLUDES OCTREOTIDE AND TWO OR MORE POLYMACTIDE-CO-GLYCOLIDE POLYMERS
CO6491060A2 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITARY DISEASES
MD4577B1 (en) Chewable veterinary compositions comprising an isoxazoline active agent and their use in the treatment and/or prophylaxis of a parasitic infection and infestation
AR090349A1 (en) COMBINATION THERAPY FOR PROLIFERATIVE DISORDERS, KIT AND USE
AR093247A1 (en) PROFILACTIC AND / OR THERAPEUTIC AGENT FOR BEHAVIOR AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL ILLNESS CONTAINING BREXPIPRAZOL OR SALTS OF THE SAME
MX2014002171A (en) Combination treatments for hepatitis c.
CL2008000442A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A CHITOSAN, A COSMETIC OR PHARMACEUTICAL ACTIVE INGREDIENT, AND A VOLATILE SOLVENT; AND ITS USE TO TREAT PSORIASIS, MICOSIS BETWEEN OTHER DISEASES.
PE20121520A1 (en) PHARMACEUTICAL FORMULATION INCLUDING RANOLAZINE AND DRONEDARONE IN THE TREATMENT OF ATRIAL FIBRILLATION
CL2013000677A1 (en) Pharmaceutical composition in the form of tablets comprising gastrointestinal microgranules containing 100 to 800 mg of rifaximin, up to 30% w / w extragranular excipients and a film-forming coating; and use to treat an infectious and / or inflammatory bowel disease, such as crohn's disease.
AR077125A1 (en) PHARMACEUTICAL COMBINATIONS USEFUL TO TREAT HCV
CL2011000798A1 (en) Use of dabigatran etexilate or a salt thereof to prepare a useful medication for the prevention of stroke in patients suffering from atrial fibrillation.
CL2011000806A1 (en) Use of dabigatran etexilate or a salt thereof to prepare a useful medication for the prevention of stroke in patients suffering from atrial fibrillation.
AR097619A1 (en) USE OF ACETIL-COA CARBOXYLASE INHIBITORS TO TREAT ACNÉ VULGARIS
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
AR114032A2 (en) 5- (3,4-DICHLORO-PHENYL) -N- (2-HYDROXY-CYCLOHEXYL) -6- (2,2,2-TRIFLUOR-ETOXY) -NICOTINAMIDE AND SALTS THEREOF
ECSP11011199A (en) FORMULATION OF OCTREOTIDE DEPOSIT WITH EXPOSURE LEVELS CONSTANTLY HIGH
MX2011012143A (en) Compositions suitable for the topical treatment of fungal infections of the skin and nails.
CL2019002172A1 (en) Therapeutic agent for liver diseases.
CL2010000524A1 (en) Use of a topical composition comprising 3.75% imiquimod and a pharmaceutically acceptable carrier to prepare a medicament useful for treating genital or perianal warts.
AR067446A1 (en) A MEDICINAL PRODUCT TO TREAT FAT LIVER THAT INCLUDES CILOSTAZOL
NI201000181A (en) USE OF DRONEDARONE TO PREPARE A MEDICINAL PRODUCT FOR THE TREATMENT OF PATIENTS WITH ARRHYTHMIA AND WHO HAVE AN INCREASED CREATININE LEVEL DUE TO THE ADMINISTRATION OF DRONEDARONE.
AR106351A1 (en) COMBINATION THAT INCLUDES AN AMINOTIOLESTER COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME AND A COMPOSITE WITH CAPACITY TO INCREASE THE LEVEL OF LEVEL H₂O₂ IN CANCER CELLS OF A SUBJECT, TO USE AS A MEDICINAL PRODUCT
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
UY31669A1 (en) "PHARMACEUTICAL FORMULATION THAT INCLUDES OXABISPIDINS / 236"

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20121218